Research reveals a mechanism that drives ataxia type 1

March 8, 2018, Baylor College of Medicine

When the protein ATAXIN1 accumulates in neurons it causes a neurodegenerative condition called spinocerebellar ataxia type 1 (SCA1), a rare disease characterized by progressive problems with balance and breathing difficulties. ATAXIN1 accumulates because of a mutation that produces an abnormal, very long version of the protein that forms clumps inside neurons. However, how accumulation of longer ATAXIN1, called polyQ-ATAXIN1, leads to neurodegeneration has remained a mystery. A group of researchers at Baylor College of Medicine, Texas Children's Hospital and the University of Minnesota reports in the journal Neuron that polyQ-ATAXIN1 and a partner molecule called capicua form a complex that is essential for neurodegeneration. They discovered that this complex is able to disrupt the expression of a number of genes in neurons in animal models of the disease. Patients with SCA1 present with similar disruption of gene expression. This discovery can potentially lead to the design of novel therapies to treat the condition.

"We wanted to understand how the accumulation of polyQ-ATAXIN1 triggers neurodegeneration," said first author Dr. Maxime Rousseaux, assistant professor of molecular and human genetics at Baylor College of Medicine. "To answer this question we worked with a mouse model of SCA1."The researchers found that when polyQ-ATAXIN1 accumulates, it remains longer inside neurons, which provides opportunities for interacting more with its usual molecular partners. One of them is capicua, a protein that is important for the regulation of .

Narrowing down the mechanism that leads to SCA1

The Zoghbi lab collaboratively with the laboratory of Dr. Harry T. Orr at University of Minnesota, investigated how polyQ-ATAXIN1 forming a complex with capicua affected the normal function of the complex. The normal ATAXIN1-capicua complex is known to be crucial for various developmental functions in other bodily tissues, so the researchers investigated whether this complex was also important for cerebellar function.

"We were surprised to find that when we removed ATAXIN1 or capicua completely from the cerebellum of mice, so no ATAXIN1-capicua complex could be formed, the animals lived a normal lifespan without neurodegeneration," said Rousseaux. "So, loss of the normal complex in the cerebellum does not result in SCA1 nor does it affect the normal development of this brain region. This suggests that the normal role of ATAXIN1-capicua complexes in the cerebellum is more subtle than in other brain areas."

On the other hand, the authors thought that the formation of polyQ-ATAXIN1-capicua complexes in the cerebellum may underlie some of the typical features of SCA1. The researchers showed that the formation of this complex is sufficient to trigger SCA1 in mice. When they altered polyQ-ATAXIN1 so it could not form a complex with capicua, the animals did not develop the condition, even though polyQ-ATAXIN1 still accumulated in their neurons. Having pinpointed that it is this protein interaction that drives toxicity, the researchers were able to discard the possibility that other mechanisms, such as ATAXIN1 RNA, also participate in the development of SCA1.

"We have learned that only when polyQ-ATAXIN1 can form a complex with capicua does it dampen the expression of a number of genes and leads to neurodegeneration. If we disrupt the interaction between polyQ-ATAXIN-1 and capicua, polyQ-ATAXIN1 is no longer toxic," said co-corresponding author Dr. Huda Zoghbi, professor of molecular and and of pediatrics and neuroscience at Baylor and director of the Jan and Dan Duncan Neurological Research Institute. "These data give us insight into the factors, in this case capicua, that make certain cells more vulnerable in SCA1."

When the researchers studied samples from patients with SCA1, they found that some of the genes whose expression was dampened in the cerebellum of mice were also dampened in the of human patients.

"This tells us that the gain of function of the polyQ-ATAXIN1-capicua complexes we are deducing from the mice seems to also apply to the human condition," said Zoghbi, who also is an investigator at the Howard Hughes Medical Institute. "

"We hope our findings will open the possibility of developing future therapeutic strategies for SCA1 by partially blocking the interaction between polyQ-ATAXIN1 and capicua," said Rousseaux. "Nevertheless, finding the other molecular players that mediate symptoms other than ataxia in SCA1 - such as the breathing and swallowing difficulties - will be an important future step."

"To me the beauty of this study is two-fold. The results nicely illustrate how important it is to understand the normal function and biochemistry of ATXN1 in order to understand how SCA1 develops," said Orr, professor and Tulloch Chair in Genetics in the Department of Laboratory Medicine and Pathology at University of Minnesota, who also is co-corresponding author of this work. "The second point is that this study very nicely demonstrates how the collaboration of groups with differing expertise and interests can make seminal advancements (and have lots of fun while doing it!)."

Explore further: Defects on regulators of disease-causing proteins can cause neurological disease

More information: Maxime W.C. Rousseaux et al, ATXN1-CIC Complex Is the Primary Driver of Cerebellar Pathology in Spinocerebellar Ataxia Type 1 through a Gain-of-Function Mechanism, Neuron (2018). DOI: 10.1016/j.neuron.2018.02.013

Related Stories

Defects on regulators of disease-causing proteins can cause neurological disease

February 22, 2018
When the protein Ataxin1 accumulates in neurons it causes a neurological condition called spinocerebellar ataxia type 1 (SCA1), a disease characterized by progressive problems with balance. Ataxin1 accumulates because of ...

Exercise provides clue to deadly ataxia

November 3, 2011
When Dr. John Fryer and Dr. Huda Zoghbi prescribed mild exercise for mice with a neurodegenerative disorder called spinocerebellar ataxia 1 (SCA1), they did not know what to expect.

New structural insight into neurodegenerative disease

March 14, 2013
A research team from the Korea Advanced Institute of Science and Technology (KAIST) released their results on the structure and molecular details of the neurodegenerative disease-associated protein Ataxin-1. Mutations in ...

Protein YAP in early life influences adult spinocerebellar ataxia pathology

January 25, 2018
Spinocerebellar ataxia is a group of neurodegenerative diseases characterized by progressive incoordination of gait, and is often associated with poor coordination of hands, speech and eye movements. There are different types ...

'Capicua' gene plays a key role in T-cell acute lymphoblastic leukaemia

September 21, 2017
Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration that is directly involved in at least 10 percent of cases of a common cancer in children, T-cell acute lymphoblastic leukaemia. ...

Molecular mechanism responsible for a neurodegenerative disease discovered

January 7, 2016
Scientists from Bern have discovered a mechanism which is responsible for the degeneration of Purkinje cells in the cerebellum in a neurodegenerative disease called Spinocerebellar ataxia type 1. The results of their study ...

Recommended for you

Genetic changes tied to rare brain bleeds in babies

December 18, 2018
(HealthDay)—Researchers say they've identified genetic mutations linked with a blood vessel defect that can lead to deadly brain bleeds in babies.

What prevents remyelination? New stem cell research reveals a critical culprit

December 18, 2018
New research on remyelination, the spontaneous regeneration of the brain's fatty insulator that keeps neurons communicating, could lead to a novel approach to developing treatments for multiple sclerosis (MS) and other inflammatory ...

Gene variant found in brain complicit in MS onset

December 18, 2018
Multiple sclerosis (MS) is an autoimmune disease affecting the function of the central nervous system. Up to now, most of the 230 genetic variants associated with the disease have been linked to changes in immune cells. However, ...

Biologists identify promising drug for ALS treatment

December 18, 2018
A drug typically used to treat hepatitis could slow the progression of ALS, also known as Lou Gehrig's disease, according to new research by University of Alberta scientists.

Communication between neural networks

December 18, 2018
The brain is organized into a super-network of specialized networks of nerve cells. For such a brain architecture to function, these specialized networks – each located in a different brain area – need to be able to communicate ...

Tiny implantable device short-circuits hunger pangs, aids weight loss

December 17, 2018
More than 700 million adults and children worldwide are obese, according to a 2017 study that called the growing number and weight-related health problems a "rising pandemic."

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.